Antibody Drug Conjugates Against Tumor Stroma: The Beginning of The End? by Mirella Zulueta, Business Development Director at Oncomatryx The potential of a technology trigger Despite many research breakthroughs over the last few decades, conventional cancer treatment strategies still face many limitations. Antibody-drug conjugates (ADCs) belong to a fairly new class of targeted cell … Leer más
War on cancer stroma: a novel pathway to treat pancreatic cancer By Laureano Simon, CEO at Oncomatryx Pancreatic cancer is the fourth most fatal cancer in men and women. Most patients with pancreatic cancer progress to either metastatic or locally advanced disease in the asymptomatic phase. Its prognosis has not improved over the past 20 years; … Leer más
Tumor microenvironment: A cancer key player to be fired Novel precision drugs that target the tumor microenvironment are entering the battlefield against cancer. Recent advances in the prevention and treatment of early stages of cancer have achieved significant success. However, little progress has been made in the development of new methods to fight late and invasive stages … Leer más
